HC Wainwright & Co. Downgrades Longboard Pharmaceuticals to Neutral, Lowers Price Target to $60
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has downgraded Longboard Pharmaceuticals from Buy to Neutral and reduced its price target from $80 to $60.
October 15, 2024 | 5:23 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
HC Wainwright & Co. downgraded Longboard Pharmaceuticals from Buy to Neutral, reducing the price target from $80 to $60, indicating a less optimistic outlook.
The downgrade from Buy to Neutral by a reputable analyst firm like HC Wainwright & Co. suggests a less favorable view on Longboard Pharmaceuticals' stock performance. The reduction in the price target from $80 to $60 further indicates a decreased expectation of the company's future stock price, likely leading to a negative short-term impact on the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100